Quarterly ResultAug 12, 2026, 06:58 AM
Pharvaris Q2 Loss €47.8M; CHAPTER-3 Data Expected 3Q2026
AI Summary
Pharvaris N.V. reported a net loss of €47.8 million for the second quarter of 2026, with cash and cash equivalents of €318 million as of June 30, 2026. The company anticipates topline data from its pivotal Phase 3 CHAPTER-3 study in 3Q2026 and noted that its deucrictibant IR NDA is under FDA review with a PDUFA date of April 23, 2027. Additionally, the EMA validated the MAA for deucrictibant IR, and a $132 million offering extended the cash runway into 2028.
Key Highlights
- Q2 2026 net loss was €47.8 million, compared to €45.5 million in Q2 2025.
- Cash and cash equivalents totaled €318 million as of June 30, 2026.
- Topline data from pivotal Phase 3 CHAPTER-3 study expected in 3Q2026.
- Deucrictibant IR NDA under FDA review with PDUFA date of April 23, 2027.
- Deucrictibant IR MAA validated by EMA in July 2026 for formal review.
- Enrollment is progressing in the CREAATE Phase 3 study for AAE-C1INH.
- Closed $132 million underwritten offering, extending cash runway into 2028.
- Research and development expenses increased to €35.0 million in Q2 2026.
Price Impact
More from PHVS